NS Pharma

NS Pharma, Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with rare and intractable diseases. Established in 1999 as a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., a Kyoto-based pharmaceutical company with a history dating back to 1919, NS Pharma serves as the U.S. headquarters for the group's global operations. The company is strategically located in Paramus, New Jersey, where it coordinates clinical development, regulatory affairs, and commercial activities to bring life-changing treatments to the North American market.

The company's primary therapeutic focus lies in neurology and hematology, with a specific emphasis on Duchenne muscular dystrophy (DMD). NS Pharma has successfully developed and commercialized VILTEPSO® (viltolarsen), an exon-skipping therapy designed to treat DMD patients with mutations amenable to exon 53 skipping. Beyond DMD, the company is actively advancing a pipeline of drug candidates targeting other rare conditions, leveraging the robust research and development capabilities of its parent company. NS Pharma operates with a patient-centric philosophy, prioritizing empathy, transparency, and collaboration with the rare disease community to address unmet medical needs.